Topics

T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

00:50 EDT 13 Sep 2019 | BioPortfolio Report Blog

T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E Pipeline Review, H1 2019


Summary


According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain Pipeline Review, H1 2019'; T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.


T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E TCell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. Tcell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in Tcell activation and proliferation.


The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain Pipeline Review, H1 2019' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.


Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Diffuse Large BCell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes Juvenile Diabetes, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Amyotrophic Lateral Sclerosis, BCell Leukemia, BCell NonHodgkin Lymphoma, Chronic Inflammation, Crohn's Disease Regional Enteritis, Down Syndrome, Extranodal Marginal Zone BCell Lymphoma MucosaAssociated Lymphoid Tissue or MALTLymphoma, Hepatitis B, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma Kahler Disease, Nodal Marginal Zone BCell Lymphoma, Non Alcoholic Fatty Liver Disease NAFLD, NonAlcoholic Steatohepatitis NASH, Primary Biliary Cirrhosis, Primary Mediastinal BCell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone BCell Lymphoma, Traumatic Brain Injury, Type 2 Diabetes and Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E

The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E targeted therapeutics and enlists all their major and minor projects

The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "T Cell Surface Glycoprotein CD3 Epsilon Chain T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500"

Quick Search

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...